Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $562,592.22 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,717 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.66, for a total value of $562,592.22. Following the completion of the transaction, the executive vice president directly owned 25,181 shares of the company’s stock, valued at $8,250,806.46. This represents a 6.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, March 3rd, Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50.
• On Friday, February 13th, Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total value of $695,199.36.
• On Monday, January 12th, Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded up $8.65 on Wednesday, reaching $327.30. 931,139 shares of the company’s stock were exchanged, compared to its average volume of 1,481,848. The business’s 50-day moving average is $357.29 and its two-hundred day moving average is $417.03. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market capitalization of $43.41 billion, a price-to-earnings ratio of 191.40 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the firm earned ($0.65) EPS. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management lifted its position in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 22 shares during the period. Howard Capital Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 24 shares during the period. Frank Rimerman Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC lifted its position in Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC lifted its position in Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 28 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ALNY shares. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Barclays began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price for the company. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. Finally, Leerink Partners decreased their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.